SELLAS Life Sciences Q2 2024 net loss $7.5M; cash $9.1M; $21M capital raise; IDMC supports REGAL

SELLAS Life Sciences Group, Inc.

2024-Q2 EPS reported -$0.33

Net loss $7.5M ($0.13/share) vs $8.8M ($0.31/share) in Q2 2023; R&D expenses $5.2M.
Cash $9.1M at June 30; subsequent $21M gross proceeds from premium-priced registered direct offering.
IDMC recommends continue Phase 3 REGAL (GPS) in AML without modifications; interim analysis expected by Q4 2024.
Phase 2a SLS009 in r/r AML: ORR 33% (60mg QW), 50% (30mg BIW), 100% in ASXL1 mutant cohort.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.